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Background: Pulmonary involvement in Niemann-Pick disease (NPD) is a common ﬁnding, especially in
type B. It usually manifests with symptoms of restrictive lung disease appearing in adulthood but
showing gradual deterioration over time. Treatment options have been dramatically limited, with whole
lung lavage offering only temporary improvement. Pulmonary alveolar proteinosis (PAP) has been pre-
viously mentioned as part of lung disease in NPD, but only in rare cases of type C2. This is the ﬁrst study
that reports the coexistence of autoimmune PAP with NPD type B.
Case presentation: An 8 year old female patient with the diagnosis of NPD type B and a 2-year history of
respiratory symptoms, presented with another episode of severe respiratory distress. Chest imaging
revealed a “crazy paving pattern”, raising concern for PAP. After admission to the intensive care unit and
application of non-invasive positive pressure ventilation, a whole lung lavage was performed with return
of a milky-appearing proteinaceous ﬂuid. Her status post-lavage was markedly improved, while genetic
testing placed the diagnosis of autoimmune PAP. The patient was initiated on inhaled GM-CSF treatment
and shows a beneﬁcial outcome to date.
Conclusions: In spite of the patient’s symptoms being consistent with NPD type of lung involvement,
clinical ﬁndings raised the suspicion of an underlying disorder, which surprisingly proved to be PAP. The
detection of anti-GM-CSF autoantibodies in our patient allowed the initiation of inhaled GM-CSF treat-
ment, which is likely to prove more beneﬁcial in her prognosis than repeated lung lavages.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Niemann-Pick disease (NPD) is a heterogenous group of lyso-
somal storage disorders inherited in an autosomal recessive
manner. In types A and B the affected gene is SMPD1, which codes
for the enzyme acid sphingomyelinase (ASM) [1]. Deﬁciency of this
enzyme causes sphingomyelin to accumulate within lysosomes of
macrophages, causing mainly hepatosplenomegaly. The prevalence
of ASM deﬁciency in the population is estimated to be 1/300,000
[2]. NPD type A is characterized by a severe neurological deterio-
ration causing death in all patients within the ﬁrst 3 years of life.
NPD type B can present later in life with predominantly visceral
symptoms, and has a more favorable prognosis, with patients64, Athens, Greece.
is), josephsonm@email.chop.
Ltd. This is an open access article usurviving into adulthood. NPD type C is caused by a mutation in the
genes NPC1 or 2, affecting the intracellular transport of cholesterol.
It is deﬁned by its progressive neurodegenerative nature which
becomes fatal usually in adolescence [3].
Presence of pulmonary involvement in Niemann-Pick disease
has been well described in various case reports. Type B is the type
most commonly associated with respiratory compromise, mainly
expressed through interstitial lung disease [4]. Symptoms of dys-
pnea and exercise intolerance become mostly apparent in adult-
hood. No effective treatment has been discovered other than lung
lavage which temporarily improves lung function [5]. However, the
disease progressively deteriorates, accounting for the mortality of
some patients of this type [6].
Pulmonary Alveolar Proteinosis (PAP) is an extremely rare dis-
ease. It is classiﬁed as autoimmune, hereditary, secondary and
idiopathic [7]. The autoimmune or acquired form accounts for 98%
of cases and is caused by the presence of anti-GM-CSF antibodies.
These autoantibodies suppress the production and effectiveness ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the alveoli, leading to the buildup of substantial amounts of sur-
factant within the distal airways. Moreover, the immune response
wanes, leading to recurrent infections. On the other hand, heredi-
tary or congenital alveolar proteinosis occurs as a result of muta-
tions in genes affecting surfactant metabolism (genes SFTPB, SFTPC,
ABCA3, NKX.2), cationic amino acid membrane transport (gene
SCF7A7), or the beta chain of the GM-CSF receptor (genes CSF2RA
and CSF2RB). Secondary forms of PAP can be provoked by a variety
of diseases including infections, hematological malignancies, im-
mune deﬁciencies and inhaled irritants or chemicals.
The coexistence of NPD with PAP has been mentioned in several
studies, but only concerning the type C of the disease. In particular,
PAP has always been described as part of the respiratory outcome of
the disease, especially the type 2C, contributing to its mortality
[8,9]. We hereby present a rare and previously undescribed pul-
monary presentation of a pediatric patient with NPD type B and
PAP.
2. Case presentation
L.A. is a female patient of Saudi Arabian descent, born in 2006
from parents that were ﬁrst-degree relatives. She was the product
of an uncomplicated pregnancy. Her birth weight was 3,000 g, and
early milestones were met at the appropriate time. Her symptoms
began at the age of 9 months with abdominal distension and
hepatosplenomegaly, but no speciﬁc diagnosis was made at that
time. At the age of 6 years, pulmonary symptoms began, with
worsening respiratory distress, cyanosis, clubbing and poor exer-
cise tolerance, requiring multiple ICU admissions. The patient
eventually became dependent on supplemental oxygen, requiring
up to 7Lpm of oxygen daily, with rapid oxyhemoglobin desatura-
tion with activity. In addition to the persistent hep-
atosplenomegaly, she developed thrombocytopenia, with easy
bruising and epistaxis. Her weight and height ranged below the 3rd
percentile, but she never showed any neurological symptoms. A
genetic study was performed and identiﬁed homozygous muta-
tions in SMPD1 gene (c.C947A), conﬁrming the diagnosis of NPD
type B. However, due to her signiﬁcant visceral and pulmonary
involvement she was not considered a candidate for a hemato-
poietic stem cell transplant (HSCT). Her younger sister also carries
the exact same mutation, but her signiﬁcantly milder pulmonary
symptoms rendered her suitable for HSCT.Fig. 1. High resolution CT scan of the chest pre- (A) and post- (B) whole lung lavage. (A) A
consisting of scattered ground-glass opacities with superimposed thickened interlobular sep
seen. (B) After whole lung lavage was performed, there is marked improvement of the previo
remaining.At the age of 8 years L.A. was referred to the Children’s Hospital
of Philadelphia for further evaluation. At the time of presentation
she appeared in severe respiratory distress and was acutely
admitted to the ICU, where non-invasive positive pressure venti-
lationwas applied due to her impending respiratory failure. CT scan
of the chest showed a diffuse “crazy paving” pattern, raising
concern for PAP (Fig. 1A). A bilateral whole lung lavage (WLL) was
subsequently performed with return of a milky-appearing ﬂuid
consisting of abundant granular PAS-positive proteinaceous mate-
rial strongly suggestive of PAP. Her clinical and radiological status
post whole lung lavage was extremely ameliorated, requiring only
½ Lpm nocturnal supplemental oxygen (Fig. 1B). Meanwhile, ge-
netic testing results identiﬁed the presence of serum GM-CSF au-
toantibodies and an abnormal STAT5 phosphorylation index test,
conﬁrming the diagnosis of autoimmune PAP. No mutations in
genes SFTPB, SFTPC, ABCA3, NKX.2, and no decrease in GM-CSF
receptors on the surface of leukocytes were identiﬁed, excluding
congenital PAP. Inhaled GM-CSF was then initiated and continued
on a daily basis. Follow-up visits for clinical evaluation and chest x-
ray were initially arranged every 2 months or sooner in case of a
decompensation in her respiratory status. After 6 months of ther-
apy, GM-CSF effect has been proved beneﬁcial with her exercise
tolerance being drastically improved, yet she continues to require
only 1/2LPM supplemental oxygen with sleep.
3. Conclusions
NPD type B has frequently been associated with respiratory
involvement. It usually consists of progressive deterioration of
pulmonary function, which most commonly manifests in adult life
and is very rarely the presenting symptom of the disease [3]. Pa-
tients may be initially asymptomatic and their respiratory disease
may be incidentally detected. When symptomatic, patients present
with mild-to-moderate dry cough and exercise intolerance, sug-
gesting interstitial lung disease [10]. The process of decline is
gradual, with patients eventually developing recurrent respiratory
infections and chronic respiratory failure [11]; however, there have
been described rare cases of rapidly progressive lung disease [10].
Radiological evidence of lung disease consists of diffuse thick-
ening of the interlobular septa suggesting mild interstitial ﬁbrosis,
along with ground glass opacities caused by the endogenous lipoid
pneumonia [12]. These two features form what is known as a
“crazy-paving” pattern, highly non-speciﬁc for the disease. Othert the initial presentation of the patient, diffuse “crazy-paving” pattern was observed,
ta. Heart size is normal. No pneumothorax, pneumomediastinum or pleural effusion is
usly mentioned opacities, with only a few septal thickenings and ground glass opacities
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emphysema [13,14]. It has been noticed though that the imaging
extent of disease does not correlate with its severity [15].
Treatment options of NPD are dramatically limited. HSCT can
potentially alleviate some of the visceral symptoms, especially if
performed early in life [16]. However there is still limited experi-
ence and possibly severe hepatic and neurological adverse effects
[17]. Recombinant sphingomyellinase therapy is still under
research and therefore it is not clinically available [18].
In cases of pulmonary involvement, bilateral or unilateral lung
lavage causes temporary improvement of respiratory function, but
does not alter the progress of the disease [19]. The ﬂuid drawn from
lavage also aids in the diagnosis of the disease, as it consists mainly
of foamy macrophages and possibly inﬂammatory cells [10]. Foamy
macrophages are highly suggestive but not speciﬁc for NPD.
The connection of PAP with Niemann-Pick disease has always
been that PAP occurs secondarily to the underlying metabolic dis-
ease [20]. However, in the case we described, the presence of GM-
CSF autoantibodies validated the autoimmune nature of PAP, which
completely alters the management and possibly the prognosis of
the patient. Inhaled GM-CSF has been proved to alter the course of
the disease in 80% of PAP patients and can be safely administered in
moderate-to-severe cases of autoimmune PAP [7,21]. Novel thera-
pies, such as transplantation of macrophage progenitors are under
investigation and have shown early positive results [22].
Had the patient’s pulmonary symptomatology been considered
secondary to her underlying metabolic dysfunction, the treatment
options would not be other than repeated lung lavagewhen needed
based on the patient’s status. The discovery of the autoimmune
aspect enabled the addition of a targeted therapy that can signiﬁ-
cantly alter the course of present respiratory dysfunction.
The present study intends to present yet another manifestation
of a patient with NPD type B. It also means to highlight that upon
suspicion of PAP in a patient with underlying disorders, physicians
must always exclude the presence of GM-CSF autoantibodies, in
order to offer the patient an efﬁcient targeted therapy and a more
tailored management.Consent
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